Chicago, Illinois-based GE HealthCare Technologies Inc. (GEHC) engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States and internationally. The company has a market cap of $29 billion and operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
Companies with a market cap of $10 billion or more are typically referred to as “large-cap stocks.” GEHC fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the medical devices industry.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
GEHC stock reached its 52-week high of $89.77 on Jan. 8 and has slipped 28.7% from that peak. The stock has fallen marginally over the past three months, underperforming the Nasdaq Composite ($NASX), which grew 2.1% over the same period.
www.barchart.comOver the longer term, the scenario stays the same. GEHC is down 17.9% over the past 52 weeks, while NASX is up 19.6% over the same period.
GEHC has been trading below its 200-day moving average since last month and also below its 50-day moving average since this month, indicating bearish momentum.
www.barchart.comGEHC has showcased an absence of organic revenue growth over the past two years, hinting at the need for new acquisitions to drive revenue growth. Moreover, its projected sales growth for the next year has been stuck at 4.4%, also suggesting lackluster demand. Additionally, GEHC’s adjusted operating margin fell by 1.7% over the past five years, showcasing falling efficiency.
When stacked against its peer in the medical devices industry, STERIS plc (STE) shares have declined 16.3% over the past 52 weeks, also outpacing GEHC.
Wall Street’s view of GEHC stock is somewhat bullish. Among the 21 analysts covering the stock, the overall consensus rating is “Moderate Buy.” Its mean price target of $82.45 offers a 29.8% upside potential.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.